MacTel Laser Study (NCT03321916) | Clinical Trial Compass
CompletedNot Applicable
MacTel Laser Study
United States9 participantsStarted 2018-02-08
Plain-language summary
This is a two armed Single Masked Pilot Study enrolling participants with Macular Telangiectasia Type 2 who will be randomized to undergo either a subthreshold photothermal treatment or a sham procedure to one eye. The participants will be followed for one year with visits at 1 month, 3 months, 6 months and 12 months post-treatment (laser or sham). Due to the small number of participants enrolled in this study the data will be analyzed by descriptive statistics and exploratory figures. Summary statistics will be produced for study and fellow eyes.
Who can participate
Age range21 Years – 79 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
✓. Males/females 21 years of age and older but less than 80 years of age;
✓. Participant must have a positive diagnosis of MacTel Type 2 in at least one eye with evidence of fluorescein leakage typical of MacTel or at least one of the other features including loss of retinal transparency/hyper-reflectivity to blue light, crystalline deposits, right angle vessels, inner/outer retinal low-reflective spaces, or hyperpigmentation not involving the center of the fovea, but no evidence of intraretinal/subretinal vascular proliferation;
✓. Participant must have an Ellipsoid Zone (EZ, aka IS/OS) break in the study eye between 0.16 - 4.0 mm2 as measured on SD-OCT;
✓. Participant's best-corrected visual acuity at least 55 letters (20/80) in the study eye;
✓. Participant must have steady fixation in the foveal or parafoveal area of each eye, adequate pupil dilation and sufficiently clear media to perform multi-modal retinal imaging and treatment;
✓. Participant must be able and willing to attend all scheduled visits.
✓. Participant should have reproducible baseline AOSLO image montages at 2 baseline imaging sessions with quality suitable to identify a minimum of 7 regions of interest (ROIs) at which reliable cone spacing measures can be made in each eye.
Exclusion criteria
✕. Participant is unable to provide informed consent;
What they're measuring
1
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: 3 months post treatment
Trial details
NCT IDNCT03321916
SponsorThe Lowy Medical Research Institute Limited
. Participant is less than 21 years of age or greater than 80 years of age; (but less than 80);
✕. Participant is medically unable to comply with study procedures or follow-up visits;
✕. Participant received intravitreal therapy for non-neovascular MacTel in the study eye and in the fellow eye, injections no sooner than 3 months prior to study treatment;
✕. Participant has nystagmus in either eye;
✕. Participant has greater than 7 diopters myopia in either eye;
✕. Participant has been diagnosed and treated for amblyopia in the study eye;
✕. Participant has significant ocular abnormalities in either eye that prevent retinal assessment, including media opacities or cataract (up to Nuclear Sclerosis +1 is allowable);